AC220 free base · Synonyms: Quizartinib

Quizartinib is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor.

For research use only. Not for human or veterinary use.

Target FLT3 Apoptosis PDGFR c-Kit

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

AC220 structure

CAS No.: 950769-58-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 365.00	BP-02113-1g	In stock	Get quote
5 g	USD 1,165.00	BP-02113-5g	In stock	Get quote
10 g	Inquire	BP-02113-10g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM.

Biological activity

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.

Identifiers

SMILES: CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC=C(OCCN5CCOCC5)C=C34)=N2)=NO1
InChIKey: MKGMVQKQNTXMPT-UHFFFAOYSA-N

Specifications

MW (average): 560.6670
Formula: C₂₉H₃₂N₆O₄S
CAS No.: 950769-58-1
Physical state: Solid
Color: White to light yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO/DMF

Documents

References

[1]. Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992.

[2]. Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42.

[3]. Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64.

Same target

Search FLT3

Same research area

Search Cancer